InflaRx GmbHJena, Schleswig-Holstein, Germany
Disclosure(s): InflaRx GmbH: Board Member, Chief Scientific Officer, Ownership Interest, Stocks/Bonds (Public Company)
85 - Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients
Thursday, October 17, 202411:15 AM – 11:30 AM US PT
